Contract Manufacturing of Biopharmaceuticals Market Report 2022-2032


Forecasts by source (mammalian, non-mammalian), by service (process development (downstream, upstream), filling and finishing operations, analytical and QC studies, packaging), by product (biologics (monoclonal antibodies ( MAB), recombinant proteins, vaccines, antisense, RNAi and molecular therapy, others), biosimilars), by company size (small, medium, large), by scale of operations (preclinical, clinical, commercial) AND market analysis Main regional and national PLUS analysis of main Businesses AND COVID-19 recovery scenarios

New York, March 01, 2022 (GLOBE NEWSWIRE) — Announces Release of “Biopharmaceuticals Contract Manufacturing Market Report 2022-2032” –

Biopharmaceuticals contract manufacturing market, 2022 to 2032 – our new study reveals the latest industry trends, R&D progress and forecast revenue

The United States is the world leader in the biopharmaceutical sector

The United States has been dubbed the “life sciences innovation capital of the world” and is a major biopharmaceutical investor. Increased demand for biologics is expected to drive the expansion of the US biopharmaceutical industry.

In terms of economic contributions and overall impacts, the biopharmaceutical sector in the United States is not only a world leader in the development of innovative drugs, vaccines and diagnostics, but it is also a highly valued industry. With a diverse employment base and an extensive research, manufacturing, and distribution infrastructure, the biopharmaceutical sector in the United States is a major and innovative component of the nation’s economy, with considerable influence on the nation’s economies.

There is a vast ecosystem of innovation in the biopharmaceutical industry that drives and sustains this success. An extensive network of collaborators supports the discovery, development and delivery of new medicines to patients through this innovation ecosystem, which is led by small and large R&D-intensive companies. This network includes, but is not limited to, venture capital and other forms of private capital; health care providers; public and private sector researchers, including academic medical researchers and private research institutes; and various other sectors. A strong biopharmaceutical innovation ecosystem and an innovation-driven policy make the United States the world leader in biopharmaceutical innovation. All these factors are expected to fuel the biopharmaceutical contract manufacturing market in the United States.

The COVID-19 pandemic has put India’s biopharmaceutical sector in the limelight

India’s biotech industry has entered a new phase of growth as the rest of the world increasingly appreciates the enormous potential of the sector to touch and improve people’s lives. In the midst of the pandemic, the successful production of contingent products like Covid-19 vaccine and indigenous diagnostic kits in such a short period has been a wonderful boon to mankind. The Biotechnology Industry Research and Development Corporation (BIRAC) and the Department of Biotechnology (DBT) have been at the forefront of enhancing the country’s creative talents and potential.

The development of alternative Covid 19 solutions has been accelerated by the Indian government’s COVID Suraksha Mission program and the Covid-19 Research Consortium, which is led by DBT and BIRAC. With significant contributions from different states, the nation is on its way to becoming a world-renowned hub of innovation and biomanufacturing. Formal biotechnology policies exist or are being developed in several states. It is the responsibility of the Make In India (MII) Facilitation Cell of the Department of Biotechnology, based at BIRAC alongside Invest India, to interact with States and assist them in formulating biotechnology policies, promoting foreign direct investment and to improve the manufacturing sector, among others. things.

What are the market drivers?
• Increased investment by CMOs for capacity expansion
• Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
• Notable growth in organic products
• Robust biopharmaceutical pipeline
• Time and cost savings offered by contractual services
• Outsourcing as a market growth engine
• Growing investments in orphan drugs

What are the market opportunities?
• Expansion of fill and finish CMOs
• Financing and investments
• Emerging economies offer lucrative growth opportunities
• Emergence of single-use bioprocessing equipment and solutions

Find out how to stay one step ahead

Our 650+ page report provides over 700 tables and charts/graphs. Read on to find out the most lucrative areas in the industry and future market prospects. Our new study allows you to assess the forecasted sales at the global market level and at the regional level. View financial results, trends, opportunities and revenue forecasts. Many opportunities remain in this growing market for contract manufacturing of biopharmaceuticals. Find out how to exploit the opportunities.

Forecasts to 2032 and other analyzes reveal trade prospects
• In addition to revenue forecasts to 2032, our new study provides you with recent results, growth rates and market shares.
• You find original analyses, with perspectives and business developments.
• Learn about qualitative analyzes (including market dynamics, drivers, opportunities, restraints and challenges), PEST analysis, Porter’s five forces, SWOT analysis, product profiles and business developments .

Discover the sales forecast for the global market and submarkets

• Mammal
• Non-mammalian

• Process development
– Downstream
– Upstream
• Filling and finishing operations
• Analytical studies and QC
• Packaging

• Organic Products
– Monoclonal antibodies (MAB)
– Recombinant Proteins
– Vaccines
– Others
• Biosimilars

size of the company
• Small
• Medium sized
• Big

Scale of operations
• Preclinical
• Clinic
• Commercial

• North America
• Europe
• Asia Pacific
• Latin America

In addition to revenue forecasts for the entire global market and segments, you will also find revenue forecasts for 5 regional markets and 17 major national markets:

By region

North America
• WE
• Canada

• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South East Asia
• Rest of Asia-Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America

Middle East and Africa
• South Africa
• Rest of the Middle East and Africa

Leading companies and market growth potential

By our calculations, the global global biopharmaceutical contract manufacturing market revenue will exceed US$xx billion in 2022. We project strong revenue growth through 2032. Our work identifies organizations with the greatest potential . Learn about their capabilities, progress, and business prospects, helping you stay ahead of the game.

How the Contract Manufacturing of Biopharmaceuticals Market Report Helps You

In summary, our 650+ page report provides you with the following insights:
• Revenue forecast to 2032 for the Biopharmaceuticals Contract Manufacturing Market, with forecasts for 5 segmentations of the Biopharmaceuticals Contract Manufacturing Market, with forecasts for 2 Sources, 4 Services, 2 Products, 2 company sizes and 3 operating scale sub-segments each planned at a global and regional level – discover industry prospects, find the most lucrative places for investment and revenue
• Revenue forecasts to 2032 for 5 regional markets and 17 key national markets – See forecast for the contract manufacturing of biopharmaceuticals market in North America, Europe, Asia-Pacific and the rest of the world . These regional markets have been divided by countries such as United States, Canada, Brazil, Mexico, Germany, France, United Kingdom, Italy, Spain, China, India, Japan, Australia, South Korea, among other major economies.
• Outlook for established companies and those looking to enter the market – including company profiles for 18 of the companies involved in the biopharmaceutical contract manufacturing market. Some of the companies featured in this report include AbbVie, Inc., AGC Biologics, Avantor, Binex Co., Ltd., Boehringer Ingelheim GmbH, Cambrex Corporation, Curia Global, Inc., FUJIFILM Diosynth Biotechnologies USA, Inc., JRS PHARMA, Jubilant Pharma Limited, Lonza, Pfizer CentreOne, ProBioGen, Rentschler Biopharma SE, Samsung Biologics, Sandoz, TOYOBO CO., LTD., Thermo Fisher Scientific and WuXi Biologics, among other prominent players.

Read the full report:

On Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Comments are closed.